Actuate Therapeutics Inc (ACTU)

Dec 17, 2024, 8:28 AM EST - 4 weeks ago

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Oct 29, 2024, 6:39 PM EDT - 2 months ago

Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development

Sep 9, 2024, 8:00 AM EDT - 4 months ago

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

Sep 5, 2024, 9:10 AM EDT - 4 months ago

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 17, 2024, 5:10 AM EDT - 5 months ago

U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline

CEP HCAI TDTH WRD YXT

Aug 14, 2024, 4:05 PM EDT - 5 months ago

Actuate Therapeutics Announces Closing of Initial Public Offering

Aug 12, 2024, 8:27 PM EDT - 5 months ago

Actuate Therapeutics Announces Pricing of Initial Public Offering

Aug 3, 2024, 12:30 AM EDT - 6 months ago

U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing

GFL OSTX

Jul 20, 2024, 4:50 AM EDT - 6 months ago

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

ARDT ARTV BLMZ CON LINE OS QMMM

May 28, 2024, 5:34 PM EDT - 8 months ago

Actuate Therapeutics Seeks IPO For Promising Pancreatic Cancer Drugs

May 28, 2024, 7:00 AM EDT - 8 months ago

Actuate Therapeutics Files Registration Statement for Initial Public Offering

May 24, 2024, 5:28 PM EDT - 8 months ago

Cancer biotech Actuate Therapeutics files for a $50 million IPO

May 24, 2024, 4:59 PM EDT - 8 months ago

Actuate Therapeutics IPO Registration Document (S-1)